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Results. Plasma TNF-a level was higher in IDC (mean 4.82; 95% confidence intewal 
3.82607 pg/ml) and CHAGAS (8.28 pg/ml; 4.98.7.94pg/ml) as compared to controls 
(1.30pg/ml; 0.93-1.63 pg/ml)(pcO.OOl). Plasma TNF-a level was higher in CHAGAS than 
in IDC after stratification for VOPmax (p=O.O49). Plasma sTNF-Rl level was higher in 
IDC only after stratification for functional class (p=O.O4). Plasma of IL-8 level were higher 
in IDC (3.18 pg/ml; 2.35-4.32 pgfml) and in CHAGAS (6.07pgIml; 4.42-8.36pg/ml) as 
compared to controls (0.84pgiml; 0.63-l .12pg/ml); plasma IL-6 concentration was higher 
in CHAGAS than in IDC after stratification for functional class (p=O.O05). Higher IL-8 lev- 
els were associated with worst clinical outcome (p=O.O3 for group I; p=O.O03 for group II); 
Plasma BNP concentrations were higher in IDC (350pglml) and in CHAGAS (444.8pgl 
ml) as compared to controls (20.3pg/ml)(p~0.001); higher BNP level was associated to 
death and heart transplantation. Plasma sFas level was similar among the groups. 
Conclusions. Systemic inflammatory and neurohumoral activation is present in patients 
with Chagas’ heart disease, differs from patients with IDC and is associated with heart 
failure severity and outcome. Thus, it should be considered in the follow-up of patients 
with Chagas’ heart disease. 
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1062-61 B-Type Natriuretic Peptide Predicts Cardiac Injury and 
Dysfunction After Subarachnoid Hemorrhage 
Povee P. Tung, Alexander Kopelnik, Nader M. Banki. Michael Lawton, Daryl Gress, 
Barbara Drew, Elyse Foster, William Young. William Parmley, Jonathan G. Zaroff. UCSF 
Medical Center, San Francisco, CA 
Background: An elevated B-type natriuretic peptlde (BNP) level is a poor prognostic 
marker in heart failure and myocardial infarction. However, its role in neurocardiogenic 
injury after subarachnoid hemorrhage @AH) is unknown. In this study, we sought to 
determine the relationship between BNP and cardiac outcomes after SAH. Methods’ We 
conducted a prospective study in 57 patients admitted for SAH. On day 1.3. and 6 after 
enrollment, we collected clinical data (serum troponin I, two-dimensional echocardiogram 
and chest radiograph) on our subjects. Serum BNP and C-reactive protein levels were 
measured as soon as possible. 
Results: The mean BNP level was 3222 518 pg/ml (range 0.8. 3330 pg/ml). Wilcoxon 
rank-sum tests showed a significant relationship between elevated BNP levels and car- 
diac endpoints, defined as a high regional wall motion score, impaired diastolic function 
(impaired relaxation, pseudonormalization, restrictive physiology), radiographic evidence 
of pulmonary edema, and an elevated troponin I level (see table). In contrast, CRP level, 
a marker of inflammation, was not associated with any short-term cardiac outcome after 
SAH. 
Conclusions: Elevated BNP, but not CRP, is associated with cardiac injury and dysfunc- 
tion after SAH. These findings are consistent with the hypothesis that neurocardiogenic 
injury after SAH is related to neurohumoral activation rather than systemic inflammation. 
BNP may be a useful marker in identifying SAH patients at high risk of cardiac complica- 
tions 
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1062-84 Phenotypic and Genotypic Heterogeneity in Cardiac 
Amyloidosis 
Enrica Perugini, Claudia Rapezzi, Fabrizio S&i, Michela Sank Giovanni Bracchetti, 
Carlo Magelli, Ornella Leone, Angelo Branzi. Institute of Cardiology, Bologna, Italy, 
Bellaria Hospital, Bologna, Italy 
Background. Most of the current knowledge on cardiac amyloidosis comes from the AL 
type (#I which precursor plasma protein is an immunoglobulln light chain) while the char- 
acteristics of myccardial involvement and the possible genotype-phenotype correlations 
in AlTR (caused by mutant transthyretin produced by the liver) remain to be defined. 
MethodsWe compared echocardiographic and clinical findings of three groups of 
patients with established amyloidotic myocardial involvement: 60 of AL type, 10 with 
ATTR Met30 mutation (in which methionine replaces valine at position 30). 16 with non- 
Met30 ATTR mutations. We also considered ATTR pts as a single group. 
Results 
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IVS = Interventricular Septal thickness; LPW = Left Posterior Wall thickness: LVEDD = 
Left Ventricular End-Diastolic Internal Dimension: LV = Left Ventricular; LA = Left Atrial 
end-systolic diameter; FS = Fractional Shoriening; 
Conclusions. Myocardial involvement is more severe in AL than in ATTR. This explains 
why AL patients develop more frequently diastolic and systolic dysfunction and clinical 
signs of heart failure. A genotype - phenotype correlation does exist within AlTR amyloi- 
dosis. A wide spectrum of morphologic and functional involvement is detectable in car- 
diac amyloidosis. This impairment is maximal in AL, intermediate in non-Met30 ATTR 
and minimal in Met30 ATTR. 
1062-85 Does Pericardiectomy Improve Outcome of Patients 
With Mixed Constriction and Restriction? 
Hirotsuau Yamada, Jeanne K. Drinko, Annitta J, Morehead, Leonardo Rodriguez, Mario 
J. Garcia, James D. Thomas, Allan L. Klein, The Cleveland Clinic Foundation, Cleveland, 
OH 
Background: Pericardiectomy can relive symptom in most patients with constrictive 
pericarditis. However, a significant subgroup of these patients has also restrictive myo- 
cardial involvement. The outcome of patients with this mixed disease has not been well 
described. Methods: Study subjects consisted of 38 patients (57 + 14 yrs. 8 female, 30 
male) who were diagnosed as having mixed physiology based on clinical history, tran- 
sthoracic and/or transesophageal echocardiography, MRI, cardiac catheterization. 
endomyocardial biopsy and/or surgical findings. Major etiology of the patients included 
coronary bypass surgery (CABG) after radiation (11), radiation therapy alone (8), CABG 
without radiation (9), idiopathic (4), heart transplantation (3). Seventeen patients treated 
with pericardiectomy (58 * 15 yrs) and 21 patients treated medically (57 * 14 yrs) were 
compared using Kaplan-Meier survival analysis. Results: There were no differences in 
age, left ventricular ejection fraction, prior radiation between both groups. Mean obsewa- 
tlon time was 4.0 f 3.8 years and maximum observation period was 13.4 years. Five 
years mortality was 51% in the pericardiectomy group and 58% in the medical therapy 
group and the survival was not significantly different between both groups (p = 0.739, fig- 
ure). Conclusions: Patients with mixed physiology of constriction and restriction have a 
high mortality rate. Pericardlectomy for these pattents may not improve their survival 
time. 
1062-86 Cardiac Function in Patients With Fukuyama-Type 
Congenital Muscular Dystrophy 
Toshio Nakanlshi, Masako Sakauchi, Hirofumi Tomimatsu. Kayoko Saitou. Makoto 
Nakazawa. Makiko Oosawa. Tokyo Women’s Medical University, Tokyo, Japan 
Backgroud: Fukuyama-type congenital muscular dystrophy (FCMD) is an autosomal 
recessive disorder characterised by generalised skeletal muscle weakness and hypoto- 
nia from early infancy and mental retardation. Mutation of fukutin gene on chromosome 
